<DOC>
	<DOC>NCT01729182</DOC>
	<brief_summary>The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).</brief_summary>
	<brief_title>Nexium Capsules LDA Specific Clinical Experience Investigation</brief_title>
	<detailed_description>Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1, A2) or healing phase (H1, H2) of SakitaMiwa classification on endoscopy). Patients who had been given Nexium for suppression of recurrence of gastric ulcer/duodenal ulcer.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Low dose Aspirin(LDA)</keyword>
	<keyword>Gastric ulcer or duodenal ulcer</keyword>
	<keyword>Nexium</keyword>
</DOC>